Conba’s Pantoprazole Sodium Enteric-coated Tablets Passed the Consistency Evaluation

Today, Zhejiang Cornbei Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") issued a notice that, recently, the company's wholly-owned subsidiary Hangzhou Cornbei Pharmaceutical Co., Ltd. (hereinafter referred to as "Hangzhou Cornbei") received the State Drug Administration (hereinafter referred to as the "State Drug Administration") issued a "drug supplement application for the approval of the drug", the drug through the consistent evaluation of generic drugs. according to the announcement, the
, the national health insurance Class B varieties, suitable for duodenum ulcers, stomach ulcers and moderate and severe reflux esophagitis treatment, its combination with kramycin and amoxixixin (or kramycin and methazole) can be used to eradicate helicobacter pylori infection, to reduce the microbial infection caused by the recurrence of duodenum ulcers and stomach ulcers.
as of this announcement day, Hangzhou Kangenbei is the first domestic manufacturer of sodium protoplasm intestinal tablets through the consistency evaluation of the State Drug Administration.
-meter net terminal data show: the corresponding retail and medical terminal market in 2019 the sales of oral preparations of pobutola, the relevant manufacturers have Takeda Pharmaceutical Co., Ltd., Liaoning Novino Pharmaceutical Co., Ltd., Hunan Jiuxian Pharmaceutical Company, Shandong Luoxin Pharmaceutical Group, etc.
Hangzhou Cornbey's sodium sodium sodium intestinal tablets have not been listed for sale.
so far, Hangzhou Kang Enbei for the drug consistency evaluation has invested about 13.94 million yuan in research and development costs.
.